# Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

> **NCT01300572** · PHASE1 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Anemia With Excess Blasts
- Secondary Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclosporine
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Indium In 111 Anti-CD45 Monoclonal Antibody BC8
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacological Study
- **RADIATION:** Total-Body Irradiation
- **RADIATION:** Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

## Key facts

- **NCT ID:** NCT01300572
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2017-10-29
- **Final completion:** 2019-11-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300572, "Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01300572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*